There is a promising new drug in the arsenal of doctors treating women with HER2 positive metastatic breast cancer, according to results of a study at the UCLA Jonsson Comprehensive Cancer Center released Saturday. The HER2-targeting antibody drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth […]